The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The anito-cel analysis covered 104 patients enrolled and leukapheresed in iMMagine-3 or GEM-AnitoFirst from September 2024 to October 2025. Anito-cel lots were successfully
Tafa-Len-R-CHOP represents a potential new first-line standard of care for patients with high-risk DLBCL or high-grade B-cell lymphoma, regardless of cell of origin
Oncologist migration patterns in the US may drive geographical care disparities, according to a poster presented at ASCO 2026.
First-line treatment with golcadomide, a first-in-class oral cereblon E3 ligase modulator, plus Pola-RCHP resulted in predictable and manageable safety outcomes without compromising Pola-RCHP
